Taylor Wessing LLP leverages its ‘broad industry knowledge’ to advise European and US life sciences clients on patent disputes across biotech, pharma and medical devices, with ’excellent UPC coordination’ capability. Co-practice head Alison Dennis leads the firm’s regulatory offering, ranging from medicine and device regulations to advertising, product safety, data protection, and competition. The firm also boasts transactional expertise, with co-head Andrew Edge being ‘highly trusted’ in M&A, IPOs, and private financing rounds. Nigel Stoate specialises in patent litigation and frequently coordinates multijurisdictional cases. Adrian Toutoungi and Charlie Adams are recognised for their ’deep expertise’ in pharmaceutical licensing and development agreements, supporting clients across a range of business models and objectives.
Legal 500 Editorial commentary
Testimonials
Collated independently by Legal 500 research team.
‘The whole Taylor Wessing IP transactions team is immersed in the biopharma ecosystem. Charlie and Adrian combine an understanding of the different business models and commercial objectives at small and larger companies, with a deep expertise in pharma licensing and development agreements and other biopharma partnering deals. It is a strong combination and has been very helpful to us as a specialty pharma company.’
‘The firm's broad industry knowledge and boutique-type service is a differentiator. If you need legal experts in the healthcare field with somebody taking immediate personal care at fair value, this is where you should go.’
‘Excellent UPC coordination. Depth of talent. Good junior partners.’
'Highly collegiate team of industry experts. Deeply committed to the maintenance of high-trust relationships. Highly practical, flexible and thoughtful; real trusted partners for our company.'
‘Adrian brings an excellent understanding of the commercial environment of the pharmaceutical business and our specific priorities when it comes to drafting agreements. He's very responsive and clear in communications, and his warmth quickly puts people at ease.’
'Andrew Edge leads our relationship with Taylor Wessing and is a highly trusted advisor with deep knowledge of our company and the business issues we deal with. We have a constantly evolving dialogue with Andrew on transactional and non-transactional matters. He has been with us since the founding of the company and is a vital partner to the business.'
Key clients
- Abbott Laboratories
- Viatris
- Piramal Enterprises
- Curonix LLC
- PAION Pharma
- Shield Therapeutics
- Apollo Therapeutics Group Limited
- Antiverse Limited
- Blue Earth Therapeutics
- Nuclera
- Shift Biosciences
- Synthon Management team
Work highlights
Acting for Abbott Laboratories coordinating extensive and commercially significant European patent litigation against Dexcom in respect of continuous glucose monitoring ("CGM") devices.
Advising Blue Earth Therapeutics on the closing of US$76.5 million Series A funding. The funding round was led by US investors, Soleus Capital and Sands Capital Management, with participation from Bracco, Woodline Partners and PBM Capital.
Representing Antiverse on the negotiation of its multi-target partnership and licensing agreement with Japanese drug discovery company Nxera Pharma.
Lawyers
Leading partners
The strongest partners in their field, leading on market-leading deals and endorsed by peers and clients alike.
Leading associates
Leading associates with regular involvement in their team's key work, and recognition from peers or clients as being ones to watch.
Charlie Adams
Practice head
Alison Dennis; Andrew Edge
Other key lawyers
Nigel Stoate; Adrian Toutoungi; Charlie Adams; Matt Royle; Andrew Payne; Mike Washbrook; Amanda Ebbutt